This company has been marked as potentially delisted and may not be actively trading. IMARA (IMRA) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsInsider TradesTrendsBuy This Stock IMRA vs. VRNA, TGTX, TLX, GRFS, LEGN, IONS, NUVL, AXSM, ALKS, and PBHShould you be buying IMARA stock or one of its competitors? The main competitors of IMARA include Verona Pharma (VRNA), TG Therapeutics (TGTX), Telix Pharmaceuticals Limited American Depositary Shares (TLX), Grifols (GRFS), Legend Biotech (LEGN), Ionis Pharmaceuticals (IONS), Nuvalent (NUVL), Axsome Therapeutics (AXSM), Alkermes (ALKS), and Prestige Consumer Healthcare (PBH). These companies are all part of the "pharmaceutical preparations" industry. IMARA vs. Verona Pharma TG Therapeutics Telix Pharmaceuticals Limited American Depositary Shares Grifols Legend Biotech Ionis Pharmaceuticals Nuvalent Axsome Therapeutics Alkermes Prestige Consumer Healthcare Verona Pharma (NASDAQ:VRNA) and IMARA (NASDAQ:IMRA) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their media sentiment, valuation, community ranking, analyst recommendations, profitability, risk, earnings, dividends and institutional ownership. Does the media favor VRNA or IMRA? In the previous week, Verona Pharma had 8 more articles in the media than IMARA. MarketBeat recorded 10 mentions for Verona Pharma and 2 mentions for IMARA. Verona Pharma's average media sentiment score of 1.34 beat IMARA's score of 0.00 indicating that Verona Pharma is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Verona Pharma 9 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive IMARA 0 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Which has better earnings and valuation, VRNA or IMRA? IMARA has lower revenue, but higher earnings than Verona Pharma. Verona Pharma is trading at a lower price-to-earnings ratio than IMARA, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioVerona Pharma$118.54M51.34-$54.37M-$2.00-37.53IMARAN/AN/A$1.49M$0.051,175.99 Is VRNA or IMRA more profitable? IMARA's return on equity of 2.12% beat Verona Pharma's return on equity.Company Net Margins Return on Equity Return on Assets Verona PharmaN/A -79.54% -43.49% IMARA N/A 2.12%2.00% Which has more volatility and risk, VRNA or IMRA? Verona Pharma has a beta of 0.2, meaning that its stock price is 80% less volatile than the S&P 500. Comparatively, IMARA has a beta of 1.09, meaning that its stock price is 9% more volatile than the S&P 500. Do insiders and institutionals believe in VRNA or IMRA? 85.9% of Verona Pharma shares are owned by institutional investors. Comparatively, 49.3% of IMARA shares are owned by institutional investors. 4.8% of Verona Pharma shares are owned by company insiders. Comparatively, 37.3% of IMARA shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term. Do analysts recommend VRNA or IMRA? Verona Pharma currently has a consensus target price of $81.50, indicating a potential upside of 8.58%. Given Verona Pharma's stronger consensus rating and higher possible upside, equities analysts plainly believe Verona Pharma is more favorable than IMARA.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Verona Pharma 0 Sell rating(s) 0 Hold rating(s) 8 Buy rating(s) 1 Strong Buy rating(s) 3.11IMARA 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Does the MarketBeat Community favor VRNA or IMRA? Verona Pharma received 310 more outperform votes than IMARA when rated by MarketBeat users. Likewise, 80.96% of users gave Verona Pharma an outperform vote while only 57.78% of users gave IMARA an outperform vote. CompanyUnderperformOutperformVerona PharmaOutperform Votes33680.96% Underperform Votes7919.04%IMARAOutperform Votes2657.78% Underperform Votes1942.22% SummaryVerona Pharma beats IMARA on 10 of the 17 factors compared between the two stocks. Get IMARA News Delivered to You Automatically Sign up to receive the latest news and ratings for IMRA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart IMRA vs. The Competition Export to ExcelMetricIMARAPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.54B$6.47B$5.33B$8.31BDividend YieldN/A2.64%5.20%4.10%P/E Ratio1,176.228.4026.7219.60Price / SalesN/A258.84395.56117.96Price / Cash75.2465.8538.3234.62Price / Book17.096.416.764.50Net Income$1.49M$143.73M$3.23B$248.40M IMARA Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)IMRAIMARAN/A$58.80-1.2%N/AN/A$1.54BN/A1,176.2241VRNAVerona Pharma1.8126 of 5 stars$74.73+3.0%$81.50+9.1%+476.9%$6.06B$118.54M-38.9230Positive NewsGap DownTGTXTG Therapeutics3.7992 of 5 stars$35.47+1.4%$40.80+15.0%+93.4%$5.63B$386.39M-354.66290Positive NewsTLXTelix Pharmaceuticals Limited American Depositary SharesN/A$16.40-0.8%$22.00+34.1%N/A$5.54B$783.21M0.00N/APositive NewsGRFSGrifols2.8646 of 5 stars$8.04+0.5%N/A+13.1%$5.53B$7.21B6.8726,300Analyst UpgradeLEGNLegend Biotech3.5271 of 5 stars$30.07+3.3%$74.73+148.5%-31.8%$5.52B$728.30M-31.651,070IONSIonis Pharmaceuticals4.3846 of 5 stars$34.47+1.3%$56.67+64.4%-12.5%$5.49B$717.25M-11.34800Positive NewsAnalyst ForecastNUVLNuvalent2.4646 of 5 stars$75.88+3.5%$115.50+52.2%+4.9%$5.43BN/A-21.8740News CoveragePositive NewsAXSMAxsome Therapeutics4.7058 of 5 stars$108.35+0.0%$172.14+58.9%+35.9%$5.33B$432.16M-18.09380Positive NewsAnalyst ForecastInsider TradeALKSAlkermes4.6109 of 5 stars$31.67+0.7%$38.33+21.0%+24.1%$5.22B$1.51B14.592,280Positive NewsPBHPrestige Consumer Healthcare3.6972 of 5 stars$87.55-1.6%$93.33+6.6%+31.1%$4.33B$1.14B20.50540Positive NewsHigh Trading Volume Related Companies and Tools Related Companies Verona Pharma Alternatives TG Therapeutics Alternatives Telix Pharmaceuticals Limited American Depositary Shares Alternatives Grifols Alternatives Legend Biotech Alternatives Ionis Pharmaceuticals Alternatives Nuvalent Alternatives Axsome Therapeutics Alternatives Alkermes Alternatives Prestige Consumer Healthcare Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:IMRA) was last updated on 5/23/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredBuffett’s favorite chart just hit 209% – here’s what that means for goldA Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the ...Golden Portfolio | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredJuly 2025 Rule Change to Impact Retirement InvestorsThere's a massive change from a new rule going into effect this July. And it's one the Big Banks are alread...Premier Gold Co | SponsoredIs President Trump Lying To You With This?President Trump’s economic transition isn’t without hardship. But what if there were a smart, tax-free way to ...Colonial Metals | SponsoredSilver Is the New Oil—And the World’s Running DryElon's Next Market Move Could Send Silver Soaring Every industry Elon Musk touches explodes—from Tesla to S...Priority Gold | SponsoredTrump’s Bitcoin Reserve is No Accident…Bitcoin's supply is being drained at unprecedented rates, but while most investors focus solely on Bitcoin, th...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding IMARA Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share IMARA With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
